Type 1 and type 2 diabetes
Conditions
Interventions
Administer insulin lispro, which has been used so far, for 1 week, then change to biosimilar at the same dose and administer for 1 week.
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 1 or type 2 diabetes who have been treated with insulin lispro for at least 3 consecutive months before the start of this study
Exclusion criteria
Exclusion criteria: 1. Patients with severe ketosis, diabetic coma or precoma 2. Patients with severe infections, before and after surgery, and with serious external injury 3. Patients with severe renal dysfunction or end-stage renal disease on dialysis 4. Patients that the attending physician deems inappropriate for this study for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| By wearing CGM, and blood glucose is continuously monitored weekly using each insulin to evaluate daily blood glucose profile (AUC). | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Change in Body weight (2) Number of occurrences of hypoglycemia (3) Variation of daily blood glucose profile (4) Comparison of average blood glucose revel from CGM data | — |
Countries
Japan
Contacts
Public ContactDaisuke Tsuriya
Hamamatsu University School of Medicine Second Division, Department of Internal Medicine
Outcome results
None listed